Advocacy intelligence hub — real-time data for patient organizations
Hoffmann-La Roche — PHASE1
University Hospital, Angers — NA
University of Hull — NA
Alnylam Pharmaceuticals — PHASE1
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
UniQure Biopharma B.V. — PHASE1, PHASE2
University College, London
CHDI Foundation, Inc.
Xenazine: FDA approved
First drug approved by FDA specifically for Huntington disease chorea.
Peggy C Nopoulos
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Travel grants
Copay Assistance1
Austedo
Teva Pharmaceuticals
Patient Assistance Programs1
Xenazine
Lundbeck
Travel Grants1
HealthWell Foundation: Huntington's Disease - Medicare Access
HealthWell Foundation
Austedo
(deutetrabenazine)Teva Pharmaceuticals
12.1 Mechanism of Action The precise mechanism by which deutetrabenazine exerts its effects in the treatment of tardive dyskinesia and chorea in patie...
Xenazine
(tetrabenazine)Orphan drugLundbeck
Vesicular Monoamine Transporter 2 Inhibitor [EPC]
12.1 Mechanism of Action The precise mechanism by which XENAZINE (tetrabenazine) exerts its anti-chorea effects is unknown but is believed to be relat...
Callum Schofield
Cambridge University Hospitals
📍 Cambridge
Peggy C Nopoulos, MD
University of Iowa
📍 Sacramento, California
Huichun Tong
Guangdong-Hongkong-Macau Institute of CNS Regeneration
Tiago A Mestre
Parkinson's Disease and Movement Disorders Centre
Mayke Oosterloo
Maastricht University Medical Center
Tianqi Yang
Guangdong-Hongkong-Macau Institute of CNS Regeneration